CHPF Regulates the Aggressive Phenotypes of Hepatocellular Carcinoma Cells via the Modulation of the Decorin and TGF-β Pathways

Chiung-Hui Liu1,2, Bo-Rui Wu1, Ying-Jui Ho3, Yin-Hung Chu1, Wei-Cheng Hsu1, To-Jung Tseng1,2, Ju-Pi Li4,5,* and Wen-Chieh Liao1,2,*

Citation: Liu, C.-H.; Wu, B.-R.; Ho, Y.-J.; Chu, Y.-H.; Hsu, W.-C.; Tseng, T.-J.; Li, J.-P.; Liao, W.-C. CHPF Regulates the Aggressive Phenotypes of Hepatocellular Carcinoma Cells via the Modulation of the Decorin and TGF-β Pathways. Cancers 2021, 13, 1261. https://doi.org/10.3390/cancers13061261

Academic Editor: Arndt Vogel

Received: 24 February 2021
Accepted: 10 March 2021
Published: 12 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Abstract: Aberrant composition of glycans in the tumor microenvironment (TME) and abnormal expression of extracellular matrix proteins are hallmarks of hepatocellular carcinoma (HCC); however, the mechanisms responsible for establishing the TME remain unclear. We demonstrate that the chondroitin polymerizing factor (CHPF), an enzyme that mediates the elongation of chondroitin sulfate (CS), is a critical elicitor of the malignant characteristics of HCC as it modifies the potent tumor suppressor, decorin (DCN). CHPF expression is frequently downregulated in HCC tumors, which is associated with the poor overall survival of HCC patients. We observed that restoring CHPF expression suppressed HCC cell growth, migration, and invasion in vitro and in vivo. Mechanistic investigations revealed that TGF-β signaling is associated with CHPF-induced phenotype changes. We found that DCN, as a TGF-β regulator, is modified by CHPF, and that it affects the distribution of DCN on the surface of HCC cells. Importantly, our results confirm that CHPF and DCN expression levels are positively correlated in primary HCC tissues. Taken together, our results suggest that CHPF dysregulation contributes to the malignancy of HCC cells, and our study provides novel insights into the significance of CS, which affects DCN expression in the TME.

Keywords: hepatocellular carcinoma; tumor microenvironment; chondroitin polymerizing factor; chondroitin sulfate; decorin

1. Introduction

Hepatocellular carcinoma (HCC) occurs in 90.73% of men and 85.42% of women suffering from liver cancer; it is the third-leading cause of cancer-related deaths worldwide [1].
Surgical resection, transarterial chemoembolization, radiofrequency ablation, and liver transplantation are the common HCC treatment options; however, these approaches are only applicable in 30% of patients, and up to 50% of patients show relapse [2]. Invasiveness and metastasis of cancer cells are the predominant factors causing high HCC relapse rates. Accumulating evidence suggests that changes in stromal cells, immune cells, extracellular proteins, and glycosylation status establish a tumor microenvironment (TME) that facilitates HCC progression [3–7]. The complex interactions between cancer cells and the TME are difficult to directly interpret from genomic information of tumor cells; therefore, exploring the mechanisms underlying the activity of cancer cells and TME interactions in HCCs may provide important information for developing novel clinical diagnosis methods and treatment options.

Glycosaminoglycans (GAGs), which are unbranched polysaccharide chains in the extracellular matrix and on the cell surface, participate in various biological interactions with the TME. GAGs that covalently link to core proteins are known as proteoglycans (PGs), and certain types of GAGs such as hyaluronan occur as free chains. Recent studies have suggested that aberrant GAGs frequently accumulate in the TME of HCCs, and that may be correlated with disease progression. Certain specific modifications of GAGs are used as biomarkers for disease diagnosis and as pharmacological targets [8–10]. Chondroitin sulfate (CS) is a major type of GAG. In the past, the functions of CS chains were only considered to be associated with structural stabilization. Various growth factors, proteases, cytokines, chemokines, and adhesion molecules have been found to interact with CS chains; therefore, the importance of CS chains in disease progression has been reevaluated [11–15].

The biosynthesis of CS chains begins with the formation of a link between N-acetylgalactosamine (GalNAc) and a common tetrasaccharide structure at a serine residue on the core protein. The next polymerization (elongation) step is catalyzed by a group of enzyme complexes (composed of CHSY1, CHPF, CHPF2, and CHSY3), which have β1–3 glucuronosyltransferase and β1–4 N-acetylgalactosaminyltransferase activities [16–19]. A single CS chain can consist of up to 50 repeating glucuronic acid (GlcA)-GalNAc subunits, which are modified with sulfate groups at various positions. Furthermore, CS epimerase (DSE and DSEL1) converts GlcA to iduronic acid within CS chains in certain cell types. Depending on the spectrotemporal expression of the polymerization and modification enzymes, CS chains can vary in lengths and numbers of sulfated units.

Several recent studies have revealed that these CS synthases and CS-modifying enzymes show tissue-specific expression profiles and play distinct roles in regulating the malignant behaviors of cancer cells. For instance, CHSY1 was upregulated in HCC and glioma tissues, and its upregulation was associated with poor outcomes in patients [20,21]. The CS epimerase DSE is also frequently upregulated in human gliomas, and its increased expression is typically associated with worse prognoses [22]. In contrast, DSE is frequently downregulated in HCC tissues [23]. Previous studies have indicated that CHPF is frequently upregulated in certain cancer types, and it may have cancer-promoting functions [24–26]. To further illustrate the functions of CS synthases during HCC progression, herein, we examined the role of CHPF, which forms the elemental structure of CS in HCC. We evaluated the correlation between clinicopathological parameters and expression of CHPF in HCC patients and explored the potential molecular mechanisms underlying its action during cancer progression. Intriguingly, we discovered that CHPF displays tumor suppressing functions in HCC cells, which is different from other types of cancer cells.

2. Results
2.1. Downregulation of CHPF in HCC

To explore the expression levels of CHPF in HCC tissues and non-cancerous liver tissues, we first measured CHPF protein levels in twelve primary HCC tissues using Western blotting. Each sample was divided into adjacent peri-tumor tissues and tumor tissues. The results indicated that CHPF protein levels were significantly downregulated in the tumor tissues, compared to their non-tumor counterparts (Paired t-test, \( p = 0.032 \); Figure 1A). To
further examine CHPF expression, 78 HCC tissue sections procured from the Chung Shan Medical University Hospital Tissue Bank were used. Immunohistochemistry revealed that dot-like precipitates of CHPF mainly occurred in the cytoplasm of adjacent non-tumor hepatocytes but were rarely observed in the surrounding stromal cells and bile duct cells (Figure 1B). To assess the relationships between CHPF expression and clinicopathological findings in HCC patients, staining intensity was scored according to the percentage of CHPF-positive parenchymal cells per sample (0, negative; +1, <20%; +2, 20–50%; +3, >50%; Figure 1C). Our results revealed that 69% of the non-tumor liver tissues expressed high CHPF levels (+2 to +3), whereas in tumor tissues, this proportion was significantly decreased (49%; Table 1). Moreover, decreased CHPF expression was correlated with advanced tumor stages (Fisher’s exact test; \( p = 0.0202 \)). A Kaplan–Meier survival analysis showed that survival rates of HCC patients with low CHPF expression (+0 to +1) was significantly lower than those of patients with high CHPF expression (+2 to +3; log-rank test; \( p = 0.038 \); Figure 1D). To confirm this observation, CHPF immunohistochemistry was performed on an independent HCC cohort (\( n = 89 \)). The results indicated that CHPF was downregulated in HCC tissues compared to non-tumor liver specimens. Consistently, low CHPF expression in HCC was significantly correlated with low survival rates (Figure S1A,B; Table S1). Taken together, our results suggest that CHPF is frequently downregulated in HCC, and that this downregulation is associated with advanced tumor stages and poor survival chances in HCC patients.

Table 1. Correlation of CHPF expression with clinicopathological features of hepatocellular carcinoma tissue.

| Factor        | Feature | CHPF Expression | \( p \) Value (Two-Sided Fisher’s Exact Test) |
|---------------|---------|-----------------|---------------------------------------------|
| Tissue types  | Non-tumor | 15 34           | 0.0275 *                                    |
|               | Tumor    | 40 38           |                                             |
| Sex           | Male     | 31 29           | 1.00                                        |
|               | Female   | 9 9             |                                             |
| Age           | <55 years | 10 7            | 0.5869                                      |
|               | ≥55 years | 30 31           |                                             |
| Tumor stage   | T1 + T2  | 20 29           | 0.0202 *                                    |
|               | T3 + T3  | 20 9            |                                             |
| Metastasis    | No       | 1 0             | 1.00                                        |
|               | Yes      | 39 38           |                                             |

* \( p < 0.05 \) was considered as statistically significant.

2.2. CHPF Affects HCC Cell Growth In Vitro and In Vivo

To investigate the potential effects of CHPF on malignant HCC cell phenotypes, we measured the CHPF protein levels in seven HCC cell lines and found that HA22T, HCC36, and Hepa1-6 expressed lower CHPF levels, whereas Hep3B and HA59T expressed higher CHPF levels (Figure 2A). We subsequently induced stable CHPF overexpression in HA22T and Hepa1-6 cells, and siRNA-mediated knockdown of CHPF in HA59T cells (Figure 2B). The CS was examined by anti-chondroitin sulfate antibody (CS56) staining and was quantified by flow cytometry. Although CS56 only reacts with highly sulfated CS [17,27], we found that overexpression of CHPF in Hepa1-6 and HA22T cells slightly increased the intensity of CS56 staining, which decreased in CHPF knockdown HA59T cells (Figure 2C). Immunostaining of CS56 on the cell surface also indicated that CHPF knockdown substantially decreased CS formation (Figure 2D). The CCK8 assay showed no significant effect of CHPF overexpression on Hepa1-6 and HA22T cell viability; however, CHPF knockdown slightly increased HA59T cell viability (Figure 3A). Furthermore, we observed that CHPF overexpression in Hepa1-6 and HA22T cells suppressed colony formation (Figure 3B). To investigate the effects of CHPF on tumor growth in vivo, we subcutaneously transplanted CHPF-overexpressing Hepa1-6 cells and control cells into NOD/SCID mice, and CHPF
overexpression significantly decreased tumor weight and volume (Figure 3C). Immunostaining of excised tumor sections revealed a decrease in the proportion of Ki67-positive cells in CHPF-overexpressing tumor tissues, indicating that CHPF may modulate HCC cell proliferation (Figure 3D).

**Figure 1.** CHPF expression in human hepatocellular carcinoma (HCC). (A) CHPF levels and quantification in non-tumor (peri-tumor) liver (N) and tumor tissue (T) of primary HCC tissues from twelve patients. (B) Immunohistochemistry of CHPF in a representative HCC tissue. Dot-like precipitations of CHPF (arrow) were observed mainly in peri-tumor tissues but rarely in stromal and tumor tissues. The scale bar indicates 50 μm. (C) Representative images of four grades of CHPF expression in primary HCC tissue (+0, negative; +1, <20%; +2, 20–50%; +3, >50%); n = 78. The scale bar indicates 150 μm. (D) Kaplan–Meier analysis of overall survival of HCC patients. The analyses were conducted according to the immunostaining of CHPF low expression (+0 and +1) and high expression (+2 and +3); p = 0.038.
Figure 2. CHPF expression in HCC cells. (A) CHPF expression in seven HCC cell lines. Protein expression was analyzed by Western blotting, and total protein was used as an internal loading control. (B) Stable CHPF overexpression in Hepa1-6 and HA22T cells. Transient CHPF knockdown in HA59T cells 48 and 72 h after siRNA transfection. Protein expression was analyzed by Western blotting, and β-actin (ACTB) was used as an internal control. (C) Surface CS56 antibody staining (an anti-chondroitin sulfate antibody) on Hepa1-6, HA22T, and HA59T transfectants was analyzed by flow cytometry with anti-mouse IgM-FITC. Nonspecific mouse IgM was used as an isotype control (Iso). *p < 0.05, ***p < 0.001. (D) Fluorescence microscopy analysis of CS56 (green); DAPI (blue) indicated the position of the nucleus. The scale bar indicates 50 µm. The cells were fixed with paraformaldehyde without permeabilization.
2.3. CHPF Regulates the Migration, Invasion, and Metastasis of HCC Cells

Transwell assays were used to study the effects of CHPF on migration and invasion of HCC cells. Our results indicated that CHPF overexpression significantly reduced FBS-induced migration and invasion abilities of Hepa1-6 and HA22T cells, whereas CHPF knockdown significantly promoted the migration and invasion abilities of HA59T cells (Figure 4A,B). A decrease in the expression of the tight junction protein ZO-1 is known to be associated with the invasive behavior of HCC cells [28-30]; therefore, we examined whether CHPF would alter ZO-1 expression in HCC cells. Immunostaining indicated that ZO-1 was expressed on the plasma membrane of two adjoining control cells, whereas CHPF knockdown decreased ZO-1 expression on the junctional surface and increased its intracellular distribution (Figure 4C). To investigate the effects of CHPF on tumor cell metastasis, CHPF-overexpressing clones and normal controls were injected into the tail
vein of NOD/SCID mice, which were killed after five weeks. In line with the in vitro results, we found that CHPF overexpression significantly reduced the number of metastatic tumors on the lung surface. Hematoxylin and eosin staining and immunohistochemistry of CHPF and Ki67 indicated decreased cell proliferation in CHPF-overexpressing tumors in the lung sections (Figure 4D).

Figure 4. Influence of CHPF on the migration, invasion, and metastasis of HCC cells. (A) CHPF regulated transwell cell migration and (B) Matrigel invasion. CHPF overexpression significantly suppressed the migration and invasion abilities of Hepa1-6 and HA22T cells, and CHPF knockdown increased the migration and invasion abilities of HA59T cells. The data presented as the means from three independent experiments ± standard deviations. Representative images are shown at the bottom; * p < 0.05; ** p < 0.01; *** p < 0.001. (C) Immunostaining of ZO-1 (green) and F-actin (red) in HA59T cells. Amplified images are shown on the right. Note that ZO-1 is expressed on the plasma membrane of two neighboring control cells (indicated by arrows); CHPF knockdown increased the intracellular distribution of ZO-1 (indicated by arrowheads). The scale bar indicates 20 µm. The percentage of plasma membrane-associated ZO-1 positive cells was shown at right. *** p < 0.001. (D) CHPF suppressed lung metastasis. The number of tumors was decreased in the CHPF-overexpressing group. Representative images are shown at the bottom. Representative images of the hematoxylin and eosin staining and immunohistochemical staining for CHPF and Ki67 in the lung sections are shown on the right; ** p < 0.01.
2.4. CHPF Modulates TGF-β Signaling and Modifies the CS Chains of Decorin (DCN)

To elucidate the possible mechanisms by which CHPF regulates the malignant behavior of HCC cells, we compared differentially expressed genes in CHPF-overexpressing cells and normal controls using RNA sequencing. Gene set enrichment analysis revealed several pathways that may be involved in this process, and we observed that the TGF-β pathway can be suppressed in CHPF-overexpressing cells (Figure S2). The TGF-β pathway is crucial for regulating ZO-1 expression [31,32], and it is associated with the invasion and metastasis of HCC [33]. To examine whether CHPF regulates TGF-β signaling, HCC cells were stimulated using TGF-β (20 ng/mL), and downstream signaling was analyzed using Western blotting. Our results indicated that CHPF overexpression attenuates TGF-β-induced Smad2 and P38 activation, whereas CHPF knockdown enhances TGF-β-induced signaling (Figure 5A). Importantly, using the TGF-β type I receptor kinase inhibitor, LY364947 successfully reversed CHPF-silencing-enhanced cell viability, cell migration, and invasion (Figure 5B,C), suggesting that TGF-β signaling participates in CHPF-regulated malignancy of HCC cells.

CS synthases-remodeled CS proteoglycans (CSPGs) are crucial for modulating signal transduction and cell–cell communication [21,23,34], and CSPG DCN is known to be a key regulator of TGF-β signaling [35–37]. Thus, we examined the influence of CHPF on DCN in HCC cells. Western blotting revealed that CHPF knockdown decreased the molecular weight of glycosaminoglycan-containing (glycanated) DCN in HA59T cells (Figure 6A), whereas CHPF overexpression increased the levels of glycanated DCN in HA22T cells (Figure S3A). Moreover, glycanated DCN diminished to the size of DCN core protein only when the GAG chains were removed by chondroitinase ABC, indicating that CHPF knockdown shortens the CS chains on DCN. To examine the effects of CHPF on DCN distribution, we performed immunostaining of DCN on HCC cells with or without cellular permeabilization, which showed that CHPF knockdown substantially decreased the distribution of extracellular DCN surrounding cells, whereas intracellular DCN was not significantly affected (Figure 6B). In contrast, CHPF overexpression increased extracellular DCN distribution on HA22T cells (Figure S3B). Consistently, the protein levels of secreted DCN were decreased in CHPF knockdown medium (Figure 6C); whereas they increased in CHPF overexpressed conditional medium (Figure S3C). We suggested that CHPF-modified DCN may enhance its stability surrounding HCC cells. To further examine the contribution of DCN in TGF-β signaling and CHPF-regulated phenotypical changes, we silenced DCN expression by siRNA. The silencing of DCN enhanced TGF-β signaling in HCC cells.
Additionally, silencing of DCN increased cell viability and cell invasion in control cells, but did not have further influences on CHPF knockdown cells (Figure 6E,F). We subsequently evaluated the correlation between CHPF expression and DCN in HCC tissues. Western blotting indicated that CHPF expression was positively correlated with the expression of glycanated DCN (Figure 6G,H), suggesting that CHPF-modified DCN may increase glycanated DCN accumulation in HCC tissues.

**Figure 6.** Decorin is modified by CHPF and is involved in malignant phenotypes in HCC cells. (A) CHPF modified the CS chains on decorin (DCN). The molecular weight of glycanated decorin was decreased after CHPF knockdown in HA59T cells. Glycanated decorin was mostly shifted to the size of core protein after 2 h of digestion with chondroitinase ABC (ChABC). These results showed no difference with regard to heparinase II treatments. Blotting of ACTB was used as an internal control. (B) Immunostaining of DCN in controls and CHPF-silenced cells. Cells with paraformaldehyde (PFA) fixation are shown at the top. Images of PFA fixation, followed by triton X100 permeabilization, are shown at the bottom. The scale bar indicates 50 µm. (C) Secreted DCN in HA59T culture medium (1 × 10⁶ of cells in 1 mL serum free medium for 24 h). Blotting of ACTB from attached cell lysate was used as a loading control. (D) Silence of DCN enhanced TGF-β signaling. Effects of DCN silencing on CHPF-mediated cell viability (E) and cell invasion (F). The HA59T cells were transfected with non-targeting control siRNAs (Ctr si), CHPF si, and/or DCN specific siRNAs (DCN si). Cells were subjected to CCK8 assay or transwell invasion assay. Data are expressed as the mean ± SD from three independent experiments. **p < 0.01. The representative images are shown on the right. (G) Western blots of DCN and CHPF in 16 primary HCC tissues. ACTB was used as a loading control. (H) Correlations between CHPF protein expression and glycanated DCN in HCC tissues; Pearson r² = 0.5257; p = 0.0015.
3. Discussion

Several recent studies have reported that CHPF is associated with cancer progression. For instance, CHPF knockdown may inhibit glioma cell growth [24], and CHPF upregulation promotes the proliferation of, and anti-apoptosis in, lung adenocarcinoma cells [25]. Moreover, CHPF can promote the tumorigenicity of malignant melanoma by regulating CDK1 [26]. Although such a tumor-promoting role of CHPF in certain types of cancer has been proposed, the direct effects of CHPF-modified CS have not yet been examined. CS covalently binds to PGs and helps them perform their normal biological functions. We reason that the expression of PGs in different cancer types may govern the influence of CHPF on cancer cells. For instance, versican was observed in various types of malignancies, including breast cancer, prostate cancer, and HCC, where it is associated with high rates of cancer relapse and poor outcomes [38–41]. In contrast, DCN and protein proteoglycan 4 demonstrate protective functions in HCC cases [42,43]. Our results demonstrate that DCN is one of the CSPGs that are modified by CHPF, and the shortened CS on DCN may alter its extracellular distribution around HCC cells.

A recent study on CHPF in HCC reported high CHPF expression in 45% (35/77) of HCC cases and low CHPF expression in all para-carcinoma tissues, which was observed using immunohistochemistry [44]. In the present study, we evaluated the expression of CHPF using Western blotting and immunohistochemistry in HCC cases treated at a local hospital and using a commercial human liver cancer tissue microarray. Our results consistently indicated that CHPF is frequently downregulated in tumor tissues, compared to the case for the adjacent non-tumor liver tissues. In addition, CHPF downregulation is associated with reduced survival spans of HCC patients. Moreover, our results demonstrate that restoring CHPF expression can decrease HCC cell growth, migration, and invasion in vitro and in vivo, and CHPF silencing in HA59T cells enhanced malignancy. Taken together, this confirms the tumor-suppressive effects of CHPF in HCC cells. We cannot rule out that the discrepancy within these studies may result from the different cell lines and HCC cohorts we used. We also supposed that the different results of immunohistochemistry may be due to the use of different antibodies for immunohistochemistry. The monoclonal antibody against CHPF used in our study produced clear cytoplasm and para-nuclear staining patterns in parenchymal cells and very little background signal in connective tissues and stromal cells (Figure 1B).

Previous studies indicated that CS synthases achieved CS polymerization via multiple combinations of CHSY1, CHSY3, and CHPF [18,19]. A different study using CHPF-knockout chondrocyte culture systems found that CHPF mainly participated in the extension of CS, whereas CHSY1 participated in both extension and initiation of CS [45]. Our results showed that CHPF knockdown decreased the size of CS on DCN but did not completely diminish the glycanated DCN, suggesting that other CS synthases also participate in CS formation on DCN, and one major function of CHPF appears to be CS extension. This result is in line with those of previous studies suggesting that each CS synthase may play a unique role in the biosynthesis of CS.

CSPG DCN is commonly expressed throughout collagenous tissues and is crucial for the adequate functioning of collagen fibers. DCN is also known as a tumor suppressor. p53- and DCN-double-knockout mice show a significantly faster rate of lymphoma development than signal p53-knockout mice [46]. Recombinant DCN, in combination with celecoxib, potentially suppresses epithelial-mesenchymal transition in colorectal cancer [47]. Reduced expression or total absence of DCN has been observed in various forms of human cancers, including HCC [48–50]. A previous report indicated that DCN gene delivery reduced liver tumor formation in a mouse model [45]. Tumor-suppressive effects of DCN are attributed to the neutralizing nature of different growth factors that have been shown to bind and inhibit the activity of all three mammalian TGF isoforms TGF-β1, -β2, and -β3, even when bound to collagen [51]. However, the influence of CS on the bioactivity of DCN has not been thoroughly investigated. Our results indicate that CHPF knockdown shortens the size of CS on DCN, which may attenuate the inhibition of TGF-β signaling. A previous
study also suggested that glycosaminoglycan chains may impede interactions of DCN core proteins with TGF-β [36]. In addition, a recent report suggested that blocking DCN secretion results in increased activation of TGF-β [52]. Our immunostaining results of DCN in HCC cells suggested that CS on DCN may facilitate its extracellular accumulation. These findings confirm the assumption that the status of CS chains on DCN may modulate their tumor-suppressive functions in the TME.

TGF-β has been reported to stimulate CHPF expression in nucleus pulposus cells by activating the Smad3, RhoA/ROCK1, and MAPK signaling pathways [53]. Our study demonstrates that CHPF elongates the CS chain on DCN and may subsequently attenuate TGF-β signaling. We thus conclude that the CS chain on DCN participates in a negative feedback loop with TGF-β signaling and CHPF expression. This may be an important mechanism for maintaining the homeostasis of TGF-β signaling in animal tissues.

4. Materials and Methods

4.1. Reagents and Antibodies

Recombinant TGF-β1 protein was purchased from PeproTech. Full length CHPF cDNA clone was purchased from OriGene. Mouse monoclonal antibody against CHPF (sc-376183) was purchased from Santa Cruz. Antibodies against p-Smad2/3 (#8828), Smad2/3 (#8658), p-AKT (#4060), AKT (#4691), p-p38 (#9211), p38 (#9212), and ZO-1 (#8193) were purchased from Cell Signaling Technology, Inc. Goat polyclonal anti-decorin (R&D Systems, catalog #AF143) was used to examine expression of Decorin. Antibodies against actin were purchased from GeneTex, Inc. CS56 antibody (C8035) was purchased from Sigma-Aldrich. The dilutions of antibodies were 1 in 2000 for Western blots, and 1 in 200 for immunostaining and flow cytometry.

TGF-β inhibitor, LY364947 (Cayman Chemical, Ann Arbor, MI, USA) was dissolved in DMSO (1.0 mg/mL) and applied to inhibit TGF-β receptor. Chondroitinase ABC and CCK8 reagent were purchased from Sigma-Aldrich. Heparinase II was purchased from R&D Systems.

4.2. Human Tissue Samples

Post-surgery frozen and paraffin-embedded HCC tissues for Western blots and immunohistochemistry were obtained from the Chung Shan Medical University Hospital (Taichung, Taiwan). This study was approved by the Ethical Committees of Chung Shan Medical University Hospital, and all patients gave informed consent to have their tissues before collection (CSMUH No: CS218075). Commercial human paired HCC tissue microarray with survival data (HLiv-HCC180Su) was purchased from Shanghai Outdo Biotech (Shanghai, China) and Pantomics, Inc (Fairfield, CA, USA).

4.3. Immunohistochemistry

Paraffin-embedded HCC tissues were incubated with anti-CHPF antibody (1:200) in 5% bovine serum albumin/PBS and 0.1% Triton X-100 (Sigma) for 16 h at 4 °C. UltraVision Quanto Detection System (Thermo Fisher Scientific Inc. Waltham, MA, USA) was used to amplify the signal. The specific immunostaining was visualized with 3,3-diaminobenzidine and counterstained with hematoxylin (Sigma, St. Louis, MO, USA). Images were scanned by TissueFAX Plus Cytometer. The distribution and positive intensity of CHPF were graded by two scorers blinded to the clinical parameters.

4.4. Cell Culture

HCC cell lines, HA22T, PLC5, HepG2, HA59T, Heb3B, and Hepa1-6, were purchased from Bioresource Collection and Research Center in the year 2014 (Hsinchu, Taiwan). HCC36 cells were ungrudgingly furnished by Prof. Lei Wan (China Medical University). Cells above were cultured in DMEM containing 4.0 mM L-glutamine and 10% FBS in 5% CO2 at 37 °C.
4.5. Transfection and RNA Interference

For overexpression experiments, Hepa1-6 cells and HA22T cells were transfected with CHPF plasmids using Lipofectamine-3000 (Invitrogen, Carlsbad, CA, USA), and empty pCMV6 plasmid was used as mock transfectant. Cells were selected with 400 µg/mL of G418 for 14 days. For siRNA knockdown experiments, ON-TARGETplus SMART-pool siRNA against CHPF, DCN, and control siRNA were purchased from Dharmacon. RNAiMAX (Thermo Fisher Scientific Inc., Waltham, MA, USA) was used for transfection and 20 nM of siRNA was used in all knockdown experiments.

4.6. Cell Invasion and Migration Assay

Transwell inserts for 24-well plate (Corning, Glendale, AZ, USA) with uncoated porous filters (pore size 8 mm) were used to evaluate cell migration, and Matrigel (BD Biosciences, San Jose, CA, USA) coated porous filters were used to examine cell invasion. Hepa1-6 (2 × 10^4 cells), HA22T (2 × 10^4 cells), and HA59T (5 × 10^4 cells) in 0.1 mL serum-free DMEM were seeded into inserts, and 0.6 mL DMEM containing 10% FBS was added in lower part of the well. Hepa1-6 cells, HA22T cells, and HA59T cells were incubated for 24 h. Cells on the upper side of the membrane were wiped. Cells moving to the other side of the filters were stained by crystal violet and counted manually. Values were shown as the average number of cells per microscopic field over three fields of each filter. Independent experiments were repeated three times.

4.7. Cell Proliferation and Colony Formation

Cells (2 × 10^3) were seeded into 96-well plates with culture medium. Living cells were analyzed by CCK8 at 0, 24, 48, and 72 h. For the anchorage-dependent colony formation assay, 500 cells were seeded in 6-well plates and incubated for 20 days. Colonies were fixed in methanol and stained with 0.1% crystal violet (Sigma, St. Louis, MO, USA) for counting. The number of anchorage colonies was counted manually.

4.8. Immunofluorescence

Cells were cultured in cover slips and fixed with 4% paraformaldehyde for 15 min at room temperature. The samples were blocked in 5% BSA-PBS for 1 h with or without 0.1% of Triton X100 (Sigma) for cell membrane permeabilization. Cells on cover slips and frozen sections of Hepa1-6 tumor tissue were stained with antibody against CS (CS56, #C8035; 1:200; Sigma), Ki67 (#ab1667; 1:100; Abcam), and CHPF. Cell Navigator™ F-actin Labeling Kit (1:1000, AAT Bioquest Inc., Sunnyvale, CA, USA) was used to visualize F-actin. DAPI was used for nuclear staining. Images were captured by ZEISS Axio Imager A2 microscope. The plasma membrane-associated ZO-1 positive cells were analyzed by microscope images (400× magnification), and 450–500 cells from 10 randomly selected fields were evaluated in each sample.

4.9. Western Blotting

Total protein lysates (20–40 µg) were separated by 8% SDS-PAGE and transferred to PVDF membrane. Total protein was measured by stain-free technology (Bio-Rad, Hercules, CA, USA). To analyze TGF-β-triggered signaling, cells were serum-starved for 3 h and then stimulated with 20 ng/mL of TGF-β for 15 min or 30 min. For the digestion of GAGs, protein lysates (40 µg) were pretreated with 0.5 units/mL protease-free chondroitinase ABC (Sigma) or heparinase II (R&D Systems, Minneapolis, MN, USA) for 2 h at 37°C. Intensity of signals on Western blotting was quantified by ImageJ software (version: 1.53 g, U. S. National Institutes of Health, Bethesda, MD, USA) (Wayne Rasband).

4.10. Metastasis and Tumor Growth Mice Models

Male NOD/SCID mice, 5 weeks of age, were purchased from National Laboratory Animal Center (Tainan, Taiwan). For tumor growth analysis, 3 × 10^6 of Hepa1-6 mock transfectants and equal number of CHPF transfectants were subcutaneously and respectively
inoculated into left and right flank (n = 5, both group). Tumor volumes were monitored for 15 days. Excised tumors were weighed and analyzed. For the tumor metastasis model, Hepa1-6 stable transfectants were injected into tail veins of mice (1 × 10^6 cells/mouse, n = 3 for each group). Mice were sacrificed 5 weeks after inoculation. The lungs were excised and surface nodules were counted. Excised tissues were paraffin-embedded for H&E stain and IHC staining.

All animal experiments in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Chung Shan Medical University Experimental Animal Center.

4.11. Statistical Analysis

All data analyses were performed using GraphPad Prism 6. Student t-test was used for statistical analyses. Paired t-test was used for the analyses of paired HCC tissue and paired Hepa1-6 tumors. Two-sided Fisher exact test was used for comparisons between CHPF expression and clinicopathologic features. Kaplan–Meier analysis and the log-rank test were used to estimate overall survival. p < 0.05 was considered statistically significant.

5. Conclusions

In conclusion, our results suggest that CHPF can modify the CS chain on DCN and regulate TGF-β signaling, thereby modulating the malignancy of HCC cells. This not only implies a pathophysiological role of CHPF in HCC cells, but also suggests significance of abnormal CS during HCC tumor progression. Understanding the biological functions and effects of CS on DCN as a tumor suppressor and on other PGs that are modified by CS synthases may offer a novel strategy for developing HCC therapeutic agents. These include recombinant CSPG, siRNAs, CSPG synthesis inhibitors, and CS degradation enzymes.

Supplementary Materials: The following are available online at https://www.mdpi.com/2072-694/13/6/1261/s1, Figure S1: (A) Immunohistochemistry of CHPF in a paraffin-embedded human HCC tissue microarray; (B) Kaplan–Meier analysis of overall survival for patients with HCC, Figure S2: Gene Set Enrichment Analysis (GSEA) of differentially expressed genes in control cells and CHPF overexpressed cells using hallmark gene sets, Figure S3: CHPF modified CS chains on decorin(DCN) in HA22T cells, Table S1: Correlation of CHPF expression with clinicopathological features of HCC tissue array.

Author Contributions: W.-C.L., B.-R.W., J.-P.L. and C.-H.L. designed the study. B.-R.W., W.-C.H., Y.-H.C., T.-J.T. and C.-H.L. performed experimental work. W.-C.L., Y.-J.H. and C.-H.L. performed data analyses. W.-C.L., W.-C.H., B.-R.W. and C.-H.L. produced the text and the figures. W.-C.L. and J.-P.L. provided leadership for the project. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by Ministry of Science and Technology, Taiwan, MOST-109-2320-B-040-007-MY3 and MOST-106-2320-B-040-009-MY3 (CH Liu), MOST-109-2320-B-040-009 (WC Liao). TissueFAX Plus Cytometer and ZEISS Axio Imager A2 microscope were performed in the Instrument Center of Chung Shan Medical University, which is supported by Ministry of Science and Technology, Ministry of Education, and Chung Shan Medical University.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethical Committees of Chung Shan Medical University Hospital (protocol code CSMUH No: CS218075).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical issues.

Conflicts of Interest: These authors have declared that no conflict of interest exists.
Abbreviations

CHPF  Chondroitin polymerizing factor  
CS  chondroitin sulfate  
DCN  decorin  
GAGs  Glycosaminoglycans  
GalNAc  N-acetylgalactosamine  
HCC  hepatocellular carcinoma  
PGs  proteoglycans  
TME  tumor microenvironment  

References

1. Laursen, L. A preventable cancer. Nature 2014, 516, S2–S3. [CrossRef]  
2. Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. Lancet 2012, 379, 1245–1255. [CrossRef]  
3. Zhang, J.; Zhang, Q.; Lou, Y.; Fu, Q.; Chen, Q.; Wei, T.; Yang, J.; Tang, J.; Wang, J.; Chen, Y.; et al. Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology 2018, 67, 1872–1889. [CrossRef]  
4. Liu, C.-H.; Lan, C.-T.; Chou, J.-F.; Tseng, T.-J.; Liao, W.-C. CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2017, 33, 347–354. [CrossRef] [PubMed]  
5. Giannelli, G.; Koudelkova, P.; Dituri, F.; Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J. Hepatol. 2016, 65, 798–808. [CrossRef] [PubMed]  
6. Mereiter, S.; Balmaña, M.; Campos, D.; Gomes, J.; Reis, C.A. Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? Cancer Cell 2019, 36, 6–16. [CrossRef] [PubMed]  
7. Peixoto, A.; Relvas-Santos, M.; Azevedo, R.; Santos, L.L.; Ferreira, J.A. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. Front. Oncol. 2019, 9, 380. [CrossRef]  
8. Akita, K.; Von Holst, A.; Furukawa, Y.; Mikami, T.; Sugahara, K.; Faissner, A. Expression of chondroitin sulfate and dermatan sulfate. Curr. Opin. Struct. Biol. 2003, 13, 612–620. [CrossRef]  
9. Salanti, A.; Clausen, T.M.; Agerbæk, M.O.; Al Nakouzi, N.; Dahlbäck, M.; Oo, H.Z.; Lee, S.; Gustavsson, T.; Rich, J.R.; Hedberg, B.J.; et al. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell 2015, 28, 500–514. [CrossRef] [PubMed]  
10. Jia, X.-L.; Li, S.-Y.; Dang, S.-S.; Cheng, Y.-A.; Zhang, X.; Wang, W.-J.; Hughes, C.E.; Caterson, B. Increased expression of chondroitin sulfate proteoglycans in rat hepatocellular carcinoma tissues. World J. Gastroenterol. 2012, 18, 3962–3976. [CrossRef] [PubMed]  
11. Sugahara, K.; Mikami, T.; Uyama, T.; Mizuguchi, S.; Nomura, K.; Kitagawa, H. Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr. Opin. Struct. Biol. 2003, 13, 612–620. [CrossRef]  
12. Akita, K.; Von Holst, A.; Furukawa, Y.; Mikami, T.; Sugahara, K.; Faissner, A. Expression of Multiple Chondroitin/Dermatan Sulfotransferases in the Neurogenic Regions of the Embryonic and Adult Central Nervous System Implies that Complex Chondroitin Sulfates Have a Role in Neural Stem Cell Maintenance. Stem Cells 2008, 26, 798–809. [CrossRef] [PubMed]  
13. Yamada, S. Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate. Curr. Drug Discov. Technol. 2008, 5, 289–301. [CrossRef] [PubMed]  
14. Mizumoto, S.; Yamada, S.; Sugahara, K. Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins. Curr. Opin. Struct. Biol. 2015, 34, 35–42. [CrossRef] [PubMed]  
15. Djerbal, L.; Lortat-Jacob, H.; Kwok, J. Chondroitin sulfates and their binding molecules in the central nervous system. Glycoconj. J. 2017, 34, 363–376. [CrossRef]  
16. Silagi, E.S.; Shapiro, I.M.; Ristub, M.V. Glycosaminoglycan synthesis in the nucleus pulposus: Dysregulation and the pathogenesis of disc degeneration. Matrix Biol. 2018, 71, 368–379. [CrossRef] [PubMed]  
17. Chen, Y.-H.; Narimatsu, Y.; Clausen, T.M.; Gomes, C.; Karlsson, R.; Steentoft, C.; Spliid, C.B.; Gustavsson, T.; Salanti, A.; Persson, A.; et al. The GAGOme: A cell-based library of displayed glycosaminoglycans. Nat. Methods 2018, 15, 881–888. [CrossRef] [PubMed]  
18. Izumikawa, T.; Koike, T.; Shiozawa, S.; Sugahara, K.; Tamura, J.-I.; Kitagawa, H. Identification of Chondroitin Sulfate Glucuronyltransferase as Chondroitin Synthase-3 Involved in Chondroitin Polymerization. J. Biol. Chem. 2008, 283, 11396–11406. [CrossRef] [PubMed]  
19. Izumikawa, T.; Uyama, T.; Okuura, Y.; Sugahara, K.; Kitagawa, H. Involvement of chondroitin sulfate synthase-3 (chondroitin synthase-3) in chondroitin polymerization through its interaction with chondroitin synthase-1 or chondroitin-polymerizing factor. Biochem. J. 2007, 403, 545–552. [CrossRef]  
20. Liu, C.-H.; Lan, C.-T.; Chou, J.-F.; Tseng, T.-J.; Liao, W.-C. CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway. Cancer Lett. 2017, 403, 280–288. [CrossRef]  
21. Liao, W.-C.; Liao, C.-K.; Tseng, T.-J.; Ho, Y.-J.; Chen, Y.-R.; Lin, K.-H.; Lai, T.-J.; Lan, C.-T.; Wei, K.-C.; Liu, C.-H. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability. Oncogenesis 2020, 9, 1–11. [CrossRef]
22. Liao, W.-C.; Liao, C.-K.; Tsai, Y.-H.; Tseng, T.-J.; Chuang, L.-C.; Lan, C.-T.; Chang, H.-M.; Liu, C.-H. DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/Erbb3 signaling. PLoS ONE 2018, 13, e0198364. [CrossRef]

23. Liao, W.-C.; Yen, H.-R.; Liao, C.-K.; Tseng, T.-J.; Lan, C.-T.; Liu, C.-H. DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCR1 axis. Am. J. Cancer Res. 2019, 9, 347–362. [PubMed]

24. Fan, Y.-H.; Xiao, B.; Lv, S.-G.; Ye, M.-H.; Zhu, X.-G.; Wu, M.-J. Lentivirus-mediated knockdown of chondroitin polymerizing factor inhibits glioma cell growth in vitro. Oncol. Rep. 2017, 38, 1149–1155. [CrossRef] [PubMed]

25. Hou, X.-M.; Zhang, T.; Da, Z.; Wu, X.-A. CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway. Pathol. Res. Pr. 2019, 215, 988–994. [CrossRef] [PubMed]

26. Sun, W.; Zhao, F.; Xu, Y.; Huang, K.; Guo, X.; Zheng, B.; Liu, X.; Luo, Z.; Kong, Y.; Xu, M.; et al. Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1. Cell Death Dis. 2020, 11, 1–13. [CrossRef]

27. Ito, Y.; Hikino, M.; Yajima, Y.; Mikami, T.; Sirko, S.; Von Holst, A.; Faisser, A.; Fukui, S.; Sugahara, K. Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library. Glycobiology 2004, 15, 593–603. [CrossRef]

28. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [CrossRef] [PubMed]

29. Orbán, E.; Szabó, E.; Lotz, G.; Kupcsikul, P.; Páska, C.; Schaff, Z.; Kiss, A. Different Expression of Ocludin and ZO-1 in Primary and Metastatic Liver Tumors. Pathol. Oncol. Res. 2008, 14, 299–306. [CrossRef]

30. Nagai, T.; Arakawa, T.; Nishio, K.; Matsumoto, K.; Hagiwara, S.; Sakurai, A.; Minami, Y.; Ida, H.; Ueshima, K.; Nishida, N.; et al. Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma. Dig. Dis. 2014, 34, 702–707. [CrossRef] [PubMed]

31. Wu, J.; Zhou, X.-J.; Sun, X.; Xia, T.-S.; Li, X.-X.; Shi, L.; Zhu, L.; Zhou, W.-B.; Wei, J.-F.; Ding, Q. RBM38 is involved in TGF-β-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer. Br. J. Cancer 2017, 117, 675–684. [CrossRef] [PubMed]

32. Viloria-Petit, A.M.; David, L.; Jia, J.Y.; Erdemir, T.; Bane, A.L.; Pinnaduwage, D.; Roncari, L.; Narimatsu, M.; Bose, R.; Moffat, J.; et al. A role for the TGF-β/Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. USA 2009, 106, 14028–14033. [PubMed]

33. Huang, J.; Qiu, M.; Wan, L.; Wang, G.; Huang, T.; Chen, Z.; Jiang, S.; Li, X.; Xie, L.; Cai, L. TGF-β1 promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression. Cell. Physiol. Biochem. 2018, 45, 1690–1699. [CrossRef] [PubMed]

34. Theoecharis, A.D.; Karamanos, N.K. Proteoglycans remodeling in cancer: Underlying molecular mechanisms. Matrix Biol. 2019, 75, 220–259. [CrossRef] [PubMed]

35. Ferdous, Z.; Wei, V.M.; Isozoo, R.; Höök, M.; Grande-Allen, K.J. Decorin-transforming Growth Factor-β Interaction Regulates Matrix Organization and Mechanical Characteristics of Three-dimensional Collagen Matrices. J. Biol. Chem. 2007, 282, 35887–35898. [CrossRef] [PubMed]

36. Hildebrand, A.; Romar, M.; Rasmussen, L.M.; Heinegård, D.; Twardzik, D.R.; Border, W.A.; Ruoslahti, E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem. J. 1994, 302, 527–534. [CrossRef] [PubMed]

37. Liu, Y.; Wang, X.; Wang, Z.; Ju, W.; Wang, D. Decorin inhibits the proliferation of HepG2 cells by elevating the expression of transforming growth factor-β receptor II. Exp. Ther. Med. 2016, 12, 2191–2195. [CrossRef] [PubMed]

38. Ricciardelli, C.; Brooks, J.H.; Suwivat, S.; Sakko, A.J.; Mayne, K.; Raymond, W.A.; Seshadri, R.; LeBaron, R.G.; Horsfall, D.J. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin. Cancer Res. 2002, 8, 1054–1060. [PubMed]

39. Ricciardelli, C.; Russell, D.L.; Ween, M.P.; Mayne, K.; Suwivat, S.; Byers, S.; Marshall, V.R.; Tilley, W.D.; Horsfall, D.J. Formation of Hyaluronan and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility. J. Biol. Chem. 2007, 282, 10814–10825. [CrossRef]

40. Ricciardelli, C.; Mayne, K.; Sykes, P.J.; Raymond, W.A.; McCaul, K.; Marshall, V.R.; Horsfall, D.J. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin. Cancer Res. 1998, 4, 963–971. [PubMed]

41. Zhangyuan, G.; Wang, F.; Zhang, H.; Jiang, R.; Tao, X.; Yu, D.; Jin, K.; Yu, W.; Liu, Y.; Yin, Y.; et al. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGF-R–PI3K–AKT pathway. Oncogene 2019, 39, 1213–1230. [CrossRef] [PubMed]

42. Ditturi, F.; Scialpi, R.; Schmidt, T.A.; Frusciante, M.; Mancarella, S.; Lupo, L.G.; Villa, E.; Giannelli, G. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro. Cell Death Dis. 2020, 11, 1–14. [CrossRef] [PubMed]

43. Reszegi, A.; Horváth, Z.; Fehé, H.; Wichmann, B.; Tátrai, P.; Kovalsky, I.; Baghy, K. Protective Role of Decorin in Primary Hepatocellular Carcinoma. Front. Oncol. 2020, 10, 645. [CrossRef]

44. Xu, Q.; Lin, W.; Tao, C.; Huang, X.; Li, J. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells. Biochem. Cell Biol. 2020, 98, 362–369. [CrossRef] [PubMed]

45. Wilson, D.G.; Phamluong, K.; Lin, W.Y.; Barck, K.; Carano, R.A.; Diehl, L.; Peterson, A.S.; Martin, F.; Solloway, M.J. Chondroitin sulfate synthase 1 (Chsy1) is required for bone development and digit patterning. Dev. Biol. 2012, 363, 413–425. [CrossRef]
46. Iozzo, R.V.; Chakrani, F.; Perrotti, D.; McQuillan, D.J.; Skorski, T.; Calabretta, B.; Eichstetter, I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. *Proc. Natl. Acad. Sci. USA* 1999, 96, 3092–3097. [CrossRef]

47. Mao, L.; Yang, J.; Yue, J.; Chen, Y.; Zhou, H.; Fan, D.; Zhang, Q.; Buraschi, S.; Iozzo, R.V.; Bi, X. Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis. *Matrix Biol.* 2021, 95, 1–14. [CrossRef]

48. Bi, X.; Tong, C.; Dockendorff, A.; Bancroft, L.; Gallagher, L.; Guzman, G.; Iozzo, R.V.; Augenlicht, L.H.; Yang, W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. *Carcinogenesis* 2008, 29, 1435–1440. [CrossRef]

49. Jarvinen, T.A.H.; Prince, S. Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition. *BioMed Res. Int.* 2015, 2015, 1–11. [CrossRef] [PubMed]

50. Horváth, Z.; Kovalszky, I.; Fullá, A.; Kiss, K.; Schaff, Z.; Iozzo, R.V.; Baghy, K. Decorin deficiency promotes hepatic carcinogenesis. *Matrix Biol.* 2014, 35, 194–205. [CrossRef] [PubMed]

51. Markmann, A.; Hauser, H.; Schönerr, E.; Kresse, H. Influence of decorin expression on transforming growth factor-β-mediated collagen gel retraction and biglycan induction. *Matrix Biol.* 2000, 19, 631–636. [CrossRef]

52. Chan, W.L.; Steiner, M.; Witkos, T.; Egerer, J.; Busse, B.; Mizumoto, S.; Pestka, J.M.; Zhang, H.; Hauser, I.; Khayal, L.A.; et al. Impaired proteoglycan glycosylation, elevated TGF-β signaling, and abnormal osteoblast differentiation as the basis for bone fragility in a mouse model for gerodermia osteodysplastica. *PLoS Genet.* 2018, 14, e1007242. [CrossRef] [PubMed]

53. Hu, B.; Xu, C.; Cao, P.; Tian, Y.; Zhang, Y.; Shi, C.; Xu, J.; Yuan, W.; Chen, H. TGF-β Stimulates Expression of Chondroitin Polymerizing Factor in Nucleus Pulposus Cells Through the Smad3, RhoA/ROCK1, and MAPK Signaling Pathways. *J. Cell. Biochem.* 2018, 119, 566–579. [CrossRef] [PubMed]